Amneal Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AMRX and other ETFs, options, and stocks.

About AMRX

Amneal Pharmaceuticals, Inc. is a medicine company, which engages in the provision of pharmaceuticals. Its product portfolio includes generics, specialty, biosciences, and product catalog. 

CEO
Chintu Patel
CEOChintu Patel
Employees
8,500
Employees8,500
Headquarters
Bridgewater, New Jersey
HeadquartersBridgewater, New Jersey
Founded
2002
Founded2002
Employees
8,500
Employees8,500

AMRX Key Statistics

Market cap
4.31B
Market cap4.31B
Price-Earnings ratio
34.52
Price-Earnings ratio34.52
Dividend yield
Dividend yield
Average volume
1.68M
Average volume1.68M
High today
$13.62
High today$13.62
Low today
$12.95
Low today$12.95
Open price
$13.00
Open price$13.00
Volume
1.02M
Volume1.02M
52 Week high
$15.42
52 Week high$15.42
52 Week low
$7.07
52 Week low$7.07

Stock Snapshot

As of today, Amneal Pharmaceuticals(AMRX) shares are valued at $13.53. The company's market cap stands at 4.31B, with a P/E ratio of 34.52.

As of 2026-06-04, Amneal Pharmaceuticals(AMRX) stock has fluctuated between $12.95 and $13.62. The current price stands at $13.53, placing the stock +4.4% above today's low and -0.7% off the high.

The Amneal Pharmaceuticals(AMRX)'s current trading volume is 1.02M, compared to an average daily volume of 1.68M.

In the last year, Amneal Pharmaceuticals(AMRX) shares hit a 52-week high of $15.42 and a 52-week low of $7.07.

In the last year, Amneal Pharmaceuticals(AMRX) shares hit a 52-week high of $15.42 and a 52-week low of $7.07.

AMRX News

Simply Wall St 41m
Is FDA-Backed Romidepsin Launch Reshaping the Investment Case for Amneal Pharmaceuticals?

Amneal Pharmaceuticals recently received U.S. Food and Drug Administration approval for its romidepsin injection solution, a ready-to-use 27.5 mg/5.5 mL oncolog...

Is FDA-Backed Romidepsin Launch Reshaping the Investment Case for Amneal Pharmaceuticals?
Investing.com 5h
Amneal Pharmaceuticals stock gains on FDA approval for cancer drug - Investing.com

...

Amneal Pharmaceuticals stock gains on FDA approval for cancer drug - Investing.com
TipRanks 6h
Amneal Pharmaceuticals announces FDA approval of romidepsin injection solution

Amneal Pharmaceuticals (AMRX) announced that the FDA has approved the company’s romidepsin injection solution, 27.5 mg/5.5 mL, supplied in single-dose, ready-to...

Analyst ratings

83%

of 6 ratings
Buy
83.3%
Hold
16.7%
Sell
0%

More AMRX News

Simply Wall St 6d
Assessing Amneal Pharmaceuticals Valuation After Recent Share Price Strength And Long Term Gains

Amneal Pharmaceuticals (AMRX) is back in focus after recent trading that left the stock with a 1 day gain of 1.7% and a 7 day move of 6.0%, prompting fresh atte...

Assessing Amneal Pharmaceuticals Valuation After Recent Share Price Strength And Long Term Gains

People also own

Based on the portfolios of people who own AMRX. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.